Patient-Oriented Evidence That Matters
Once-Weekly Semaglutide Is an Effective Adjunct for Weight Loss in Adults without Diabetes Who Are Overweight or Obese
Am Fam Physician. 2021 Jul ;104(1):96-97.
Is once-weekly subcutaneous semaglutide (Ozempic) an effective adjunct to intensive behavioral therapy for adults without diabetes mellitus who are overweight or obese?
Once-weekly subcutaneous semaglutide used as an adjunct to intensive behavioral therapy significantly improves the likelihood that adults without diabetes who are overweight or obese will lose at least 5% of their baseline body weight compared with placebo (number needed to treat = 2.4). (Level of Evidence = 1b)
Although semaglutide helps reduce weight and improve glucose control in adults with type 2 diabetes, its effectiveness as an adjunct for weight loss in adults without diabetes who are overweight or obese is uncertain. The investigators identified adults without diabetes, 18 years or older, who reported at least one unsuccessful dietary effort to lose weight and had a body mass index (BMI) of 27 kg per m2 or higher with at least one weight-related comorbidity (e.g., cardiovascular disease, hyper-lipidemia, hypertension, obstructive sleep apnea) or a BMI of 30 kg per m2 or higher. Most patients were women (81%) and White (76%) with a mean age of 46 years and mean BMI of 38 kg per m2. Eligible patients (n = 611) randomly received (concealed allocation assignment) once-weekly subcutaneous semaglutide (initially 0.25 mg, with dose titrated as tolerated every four weeks to a target dosage of 2.4 mg per week at week 16) or matched placebo. Participants also received a low-calorie diet (1,000 to 1,200 kcal per day) for the first eight weeks, followed by 1,200 to 1,800 kcal per day for the remainder of the 68 weeks. In addition, all participants received an exercise prescription and 30 individual intensive behavioral visits with a dietitian. Complete follow-up occurred for 92.8% of participants at 68 weeks.
Using intention-to-treat analysis, participants in the semaglutide group lost significantly more weight than in the placebo group (estimated mean body weight change from baseline:
POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.
For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.
To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.
This series is coordinated by Sumi Sexton, MD, editor-in-chief.
A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.
Want to use this article elsewhere? Get Permissions